Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
24M
-
Shares change
-
+103K
-
Total reported value, excl. options
-
$1.58B
-
Value change
-
+$28.5M
-
Put/Call ratio
-
1.06
-
Number of buys
-
82
-
Number of sells
-
-78
-
Price
-
$65.84
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q4 2017
210 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2017.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24M shares
of 207M outstanding shares and own 11.57% of the company stock.
Largest 10 shareholders include BB BIOTECH AG (2.36M shares), Meditor Group Ltd (2.32M shares), Pentwater Capital Management LP (1.93M shares), BlackRock Inc. (1.51M shares), FMR LLC (1.25M shares), STATE STREET CORP (1.17M shares), CREDIT SUISSE AG/ (1.02M shares), Vanguard Group Inc (930K shares), Partner Fund Management, L.P. (870K shares), and Boxer Capital, LLC (800K shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.